{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T11:55:43Z","timestamp":1774958143570,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","nutritionjrnl.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.nut.2014.07.016","type":"journal-article","created":{"date-parts":[[2014,8,6]],"date-time":"2014-08-06T06:46:31Z","timestamp":1407307591000},"page":"239-243","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Surprising results of a supportive integrated therapy in myelofibrosis"],"prefix":"10.1016","volume":"31","author":[{"given":"Antonio","family":"Macci\u00f2","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Gramignano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clelia","family":"Madeddu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nut.2014.07.016_bib1","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2010.29.8711","article-title":"Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies","volume":"29","author":"Tefferi","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nut.2014.07.016_bib2","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.2012.42.0240","article-title":"Improving survival trends in primary myelofibrosis: an international study","volume":"30","author":"Cervantes","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nut.2014.07.016_bib3","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cncr.22365","article-title":"The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international internet-based survey of 1179 MPD patients","volume":"109","author":"Mesa","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.nut.2014.07.016_bib4","first-page":"89","article-title":"Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes","volume":"29","author":"Mughal","year":"2014","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.nut.2014.07.016_bib5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s12185-010-0530-z","article-title":"Molecular aspects of myeloproliferative neoplasms","volume":"91","author":"Delhommeau","year":"2010","journal-title":"Int J Hematol"},{"key":"10.1016\/j.nut.2014.07.016_bib6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/ajh.23384","article-title":"Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management","volume":"88","author":"Tefferi","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.nut.2014.07.016_bib7","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A\u00a0double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.nut.2014.07.016_bib8","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","article-title":"Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis","volume":"122","author":"Cervantes","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.nut.2014.07.016_bib9","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1182\/blood.V120.21.1733.1733","article-title":"Improvement in weight and total cholesterol and their association with survival in ruxolitinib-treated patients with myelofibrosis from COMFORT-I","volume":"120","author":"Mesa","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.nut.2014.07.016_bib10","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1111\/j.1582-4934.2008.00408.x","article-title":"Interleukin-6 and leptin as markers of energy metabolic changes in advanced ovarian cancer patients","volume":"13","author":"Macci\u00f2","year":"2009","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.nut.2014.07.016_bib11","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ygyno.2011.12.435","article-title":"A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecologic cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life","volume":"124","author":"Macci\u00f2","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.nut.2014.07.016_bib12","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1517\/14656566.2012.734297","article-title":"Current pharmacotherapy options for\u00a0cancer anorexia and cachexia","volume":"13","author":"Macci\u00f2","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.nut.2014.07.016_bib13","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.nut.2005.06.003","article-title":"Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy","volume":"22","author":"Gramignano","year":"2006","journal-title":"Nutrition"},{"key":"10.1016\/j.nut.2014.07.016_bib14","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00109-009-0547-z","article-title":"Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia","volume":"88","author":"Mantovani","year":"2010","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.nut.2014.07.016_bib15","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1258\/ebm.2011.011028","article-title":"Role of nuclear factor \u03baB-mediated inflammatory pathways in cancer-related symptoms and their regulation by nutritional agents","volume":"236","author":"Gupta","year":"2011","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.nut.2014.07.016_bib16","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/ajh.10076","article-title":"Successful treatment of anemia in idiopathic myelofibrosis with recombinant human erythropoietin","volume":"70","author":"Hasselbach","year":"2002","journal-title":"Am J Hematol"},{"key":"10.1016\/j.nut.2014.07.016_bib17","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1159\/000097463","article-title":"Recombinant human erythropoietin for the treatment of anemia in patients with chronic idiopathic myelofibrosis","volume":"117","author":"Tsiara","year":"2007","journal-title":"Acta Haematol"},{"key":"10.1016\/j.nut.2014.07.016_bib18","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1634\/theoncologist.2010-0020","article-title":"Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-beta for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open-label, randomized controlled study","volume":"15","author":"Macci\u00f2","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.nut.2014.07.016_bib19","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.nut.2014.07.016_bib20","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.clnu.2011.04.001","article-title":"Accuracy of direct segmental multi-frequency bioimpedance analysis in the assessment of total body and segmental body composition in middle-aged adult population","volume":"30","author":"Ling","year":"2011","journal-title":"Clin Nutr"},{"key":"10.1016\/j.nut.2014.07.016_bib21","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1046\/j.1523-5394.1998.006003143.x","article-title":"A multidimensional measure\u00a0of fatigue for use with cancer patients","volume":"6","author":"Stein","year":"1998","journal-title":"Cancer Pract"},{"key":"10.1016\/j.nut.2014.07.016_bib22","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.nut.2014.07.016_bib23","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1080\/1071576021000005302","article-title":"Use of N,N-dimethyl-P-phenylenediamine to evaluate the oxidative status of human plasma","volume":"36","author":"Verde","year":"2002","journal-title":"Free Radic Res"},{"key":"10.1016\/j.nut.2014.07.016_bib24","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","article-title":"Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report","volume":"122","author":"Tefferi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.nut.2014.07.016_bib25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2141.1993.tb04658.x","article-title":"Serum erythropoietin in patients with myelofibrosis with myeloid metaplasia","volume":"83","author":"Barosi","year":"1993","journal-title":"Br J Haematol"},{"key":"10.1016\/j.nut.2014.07.016_bib26","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2141.2004.05229.x","article-title":"Erythropoietin treatment of the anemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature","volume":"127","author":"Cervantes","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.nut.2014.07.016_bib27","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/B978-0-12-410473-0.00011-8","article-title":"Mechanism-based therapeutic approaches to cachexia","volume":"92","author":"Penna","year":"2013","journal-title":"Vitam Horm"}],"container-title":["Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0899900714003554?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0899900714003554?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T23:25:59Z","timestamp":1598138759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0899900714003554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0899900714003554"],"URL":"https:\/\/doi.org\/10.1016\/j.nut.2014.07.016","relation":{},"ISSN":["0899-9007"],"issn-type":[{"value":"0899-9007","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Surprising results of a supportive integrated therapy in myelofibrosis","name":"articletitle","label":"Article Title"},{"value":"Nutrition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nut.2014.07.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}